SCHEMBL24252970

SCHEMBL24252970

COc1ccc(CNc2ccnc3cc(-c4cc(Cl)ccc4OC)ccc23)c(OC)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 2/20 0.50
ADRA1D P25100 2/20 0.50
ADRA1A P35348 2/20 0.50
ADRA1B P35368 2/20 0.50
TGFBR1 P36897 2/20 0.50
CYP1A2 P05177 7/20 0.48
CYP3A4 P08684 6/20 0.48
CYP2C19 P33261 6/20 0.48
TSHR P16473 5/20 0.48
ALDH1A1 P00352 4/20 0.48
LMNA P02545 4/20 0.48
CLK4 Q9HAZ1 4/20 0.48
HSD17B10 Q99714 3/20 0.48
CYP2C9 P11712 2/20 0.48
FERMT2 Q96AC1 1/20 0.47
CYP2D6 P10635 5/20 0.46
CCR1 P32246 1/20 0.46
GLA P06280 1/20 0.46
USP2 O75604 2/20 0.46
MEN1 O00255 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30451870 0.92 CYP1A2 (0.55) HTR1AADRA1DADRA1AADRA1BCYP1A2
SCHEMBL24252882 0.92 CYP1A2 (0.55) HTR1AADRA1DADRA1AADRA1BCYP1A2
SCHEMBL30451317 0.86 CYP1A2 (0.46) CYP1A2CYP3A4CYP2C19TSHRALDH1A1
SCHEMBL24252808 0.86 CYP1A2 (0.46) CYP1A2CYP3A4CYP2C19TSHRALDH1A1
SCHEMBL30467726 0.82 CYP1A2 (0.43) CYP1A2CYP3A4CYP2C19TSHRALDH1A1
SCHEMBL24252447 0.79 HTR1A (0.58) HTR1AADRA1DADRA1AADRA1BCYP1A2
SCHEMBL24252403 0.79 CNR1 (0.43) CYP1A2CYP3A4CYP2C19TSHRALDH1A1
SCHEMBL30467579 0.79 CYP1A2 (0.41) TGFBR1CYP1A2CYP3A4CYP2C19TSHR
SCHEMBL25256525 0.79 CYP1A2 (0.45) CYP1A2CYP3A4CYP2C19TSHRALDH1A1
SCHEMBL30462703 0.79 CYP1A2 (0.45) CYP1A2CYP3A4CYP2C19TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 US disclosed
US-12509474-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2025-12-30 US disclosed
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
CN-116947903-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-10-27 CN disclosed
CN-116261564-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-06-13 CN disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 EP disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 HTR1A 2666/4885ADRA1D 3729/4885ADRA1A 4499/4885
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 HTR1A 2666/4885ADRA1D 3729/4885ADRA1A 4499/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 HTR1A 2666/4885ADRA1D 3729/4885ADRA1A 4499/4885
US-12509474-B2 Inhibitors of complement factors and uses thereof SSB, UACA, CFH HTR1A 3306/4885ADRA1D 2780/4885ADRA1A 3363/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 HTR1A 1126/4885ADRA1D 1860/4885ADRA1A 2633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.